{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:55:40Z","timestamp":1761540940413},"reference-count":3,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T00:00:00Z","timestamp":1249344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Currently, efficacy of a new factor concentrate is mostly judged by its ability to achieve haemostasis after a bleeding episode. However, in patients on prophylaxis, the effectiveness in preventing bleeds, and thus joint damage, is most important. An albumin\u2010free recombinant factor VIII (FVIII) concentrate was introduced in the Netherlands in 2004. In this study, the efficacy of a new recombinant plasma\/albumin\u2010free FVIII concentrate (rAHF\u2010PFM, Advate\u00ae) was assessed by comparing bleeding frequency and factor consumption before and after switching to the new product, on both prophylactic and on\u2010demand treatment. Eighty\u2010two previously treated haemophilia A patients with \u2003at least 1\u2010year clinical follow\u2010up were included in this study. Data on 410 patient\u2010years were analysed, including 165 patient\u2010years on other clotting factor products, and 245 patient\u2010years on the new concentrate. In total, 19\u2003628\u2003368\u2003IU of other factor concentrates were administered, to treat 839 bleeds, including 578 joint bleeds and cover 104\u2003years of prophylactic treatment. For rAHF\u2010PFM 33\u2003082\u2003250\u2003IU FVIII, were used to treat 1144 bleeds, including 734 joint bleeds and cover 175\u2003years of prophylactic treatment. No inhibitors, seroconversions or other serious adverse events were observed. Annual FVIII consumption per kg and annual number of joint bleeds before and after switching to the new albumin\u2010free recombinant factor concentrate were similar in all patients. In conclusion, rAHF\u2010PFM is equally effective as other clotting factor concentrates for prophylactic treatment in severe haemophilia.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2009.02079.x","type":"journal-article","created":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T10:13:42Z","timestamp":1249380822000},"page":"1215-1218","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment"],"prefix":"10.1111","volume":"15","author":[{"given":"I.","family":"DEN UIJL","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. P.","family":"MAUSER\u2010BUNSCHOTEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"ROOSENDAAL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"SCHUTGENS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"FISCHER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,10,26]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00932.x"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03032.x"},{"key":"e_1_2_7_4_2","first-page":"555","article-title":"Anti\u2010hemophilic factor (recombinant), plasma\/albumin\u2010free method (octocog\u2010alpha; ADVATE\u00ae) in the management of hemophilia A","volume":"3","author":"Shapiro AD","year":"2007","journal-title":"Vasc Health Risk Manag"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2009.02079.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2009.02079.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:21:05Z","timestamp":1697242865000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2009.02079.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,26]]},"references-count":3,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1111\/j.1365-2516.2009.02079.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02079.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,26]]}}}